Supernus Announces Third Quarter 2023 Financial Results
ROCKVILLE, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter of 2023, and associated Company developments.
Related news for (SUPN)
- Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
- Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
- supernus pharmaceuticals to host webcast to review open-label phase 2a study of spn-820 for the treatment of major depressive disorder
- supernus pharmaceuticals to participate in the td cowen 4th annual novel mechanisms in neuropsychiatry summit
- supernus pharmaceuticals to participate in the 2024 wells fargo healthcare conference